CERN-MEDICIS: A Review Since Commissioning in 2017

Research output: Contribution to journalArticlepeer-review

Standard

CERN-MEDICIS: A Review Since Commissioning in 2017. / Duchemin, Charlotte; Fernandes Pinto Ramos, João Pedro; Stora, Thierry; Ahmed, Essraa; Aubert, Elodie; Audouin, Nadia; Barbero, Ermano; Barozier, Vincent; Bernardes, Ana-Paula; Bertreix, Philippe; Barbero, Ermanno; Bruchertseifer, Frank; Catherall, Richard; Chevallay, Eric; Christodoulou, Pinelopi; Cocolios, Thomas Elias; Comte, Jeremie; Crepieux, Bernard ; Deschamps, Matthieu; Dockx, Kristof; Dorsival, Alexandre; Fedosseev, Valentin N.; Fernier, Pascal; Formento-Cavaier, Roberto.

In: Frontiers in Medicine, Vol. 8, 693682, 15.07.2021, p. 1-11.

Research output: Contribution to journalArticlepeer-review

Harvard

Duchemin, C, Fernandes Pinto Ramos, JP, Stora, T, Ahmed, E, Aubert, E, Audouin, N, Barbero, E, Barozier, V, Bernardes, A-P, Bertreix, P, Barbero, E, Bruchertseifer, F, Catherall, R, Chevallay, E, Christodoulou, P, Cocolios, TE, Comte, J, Crepieux, B, Deschamps, M, Dockx, K, Dorsival, A, Fedosseev, VN, Fernier, P & Formento-Cavaier, R 2021, 'CERN-MEDICIS: A Review Since Commissioning in 2017', Frontiers in Medicine, vol. 8, 693682, pp. 1-11. https://doi.org/10.3389/fmed.2021.693682

APA

Duchemin, C., Fernandes Pinto Ramos, J. P., Stora, T., Ahmed, E., Aubert, E., Audouin, N., Barbero, E., Barozier, V., Bernardes, A-P., Bertreix, P., Barbero, E., Bruchertseifer, F., Catherall, R., Chevallay, E., Christodoulou, P., Cocolios, T. E., Comte, J., Crepieux, B., Deschamps, M., ... Formento-Cavaier, R. (2021). CERN-MEDICIS: A Review Since Commissioning in 2017. Frontiers in Medicine, 8, 1-11. [693682]. https://doi.org/10.3389/fmed.2021.693682

Vancouver

Duchemin C, Fernandes Pinto Ramos JP, Stora T, Ahmed E, Aubert E, Audouin N et al. CERN-MEDICIS: A Review Since Commissioning in 2017. Frontiers in Medicine. 2021 Jul 15;8:1-11. 693682. https://doi.org/10.3389/fmed.2021.693682

Author

Duchemin, Charlotte ; Fernandes Pinto Ramos, João Pedro ; Stora, Thierry ; Ahmed, Essraa ; Aubert, Elodie ; Audouin, Nadia ; Barbero, Ermano ; Barozier, Vincent ; Bernardes, Ana-Paula ; Bertreix, Philippe ; Barbero, Ermanno ; Bruchertseifer, Frank ; Catherall, Richard ; Chevallay, Eric ; Christodoulou, Pinelopi ; Cocolios, Thomas Elias ; Comte, Jeremie ; Crepieux, Bernard ; Deschamps, Matthieu ; Dockx, Kristof ; Dorsival, Alexandre ; Fedosseev, Valentin N. ; Fernier, Pascal ; Formento-Cavaier, Roberto. / CERN-MEDICIS: A Review Since Commissioning in 2017. In: Frontiers in Medicine. 2021 ; Vol. 8. pp. 1-11.

Bibtex - Download

@article{8ae1cc2cf39d4ed680c3aff352c19a46,
title = "CERN-MEDICIS: A Review Since Commissioning in 2017",
abstract = "The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.",
keywords = "CERN MEDICIS, Radionuclides, CERN, Medical",
author = "Charlotte Duchemin and {Fernandes Pinto Ramos}, {Jo{\~a}o Pedro} and Thierry Stora and Essraa Ahmed and Elodie Aubert and Nadia Audouin and Ermano Barbero and Vincent Barozier and Ana-Paula Bernardes and Philippe Bertreix and Ermanno Barbero and Frank Bruchertseifer and Richard Catherall and Eric Chevallay and Pinelopi Christodoulou and Cocolios, {Thomas Elias} and Jeremie Comte and Bernard Crepieux and Matthieu Deschamps and Kristof Dockx and Alexandre Dorsival and Fedosseev, {Valentin N.} and Pascal Fernier and Roberto Formento-Cavaier",
note = "Score=10",
year = "2021",
month = jul,
day = "15",
doi = "10.3389/fmed.2021.693682",
language = "English",
volume = "8",
pages = "1--11",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media SA",

}

RIS - Download

TY - JOUR

T1 - CERN-MEDICIS: A Review Since Commissioning in 2017

AU - Duchemin, Charlotte

AU - Fernandes Pinto Ramos, João Pedro

AU - Stora, Thierry

AU - Ahmed, Essraa

AU - Aubert, Elodie

AU - Audouin, Nadia

AU - Barbero, Ermano

AU - Barozier, Vincent

AU - Bernardes, Ana-Paula

AU - Bertreix, Philippe

AU - Barbero, Ermanno

AU - Bruchertseifer, Frank

AU - Catherall, Richard

AU - Chevallay, Eric

AU - Christodoulou, Pinelopi

AU - Cocolios, Thomas Elias

AU - Comte, Jeremie

AU - Crepieux, Bernard

AU - Deschamps, Matthieu

AU - Dockx, Kristof

AU - Dorsival, Alexandre

AU - Fedosseev, Valentin N.

AU - Fernier, Pascal

AU - Formento-Cavaier, Roberto

N1 - Score=10

PY - 2021/7/15

Y1 - 2021/7/15

N2 - The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.

AB - The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.

KW - CERN MEDICIS

KW - Radionuclides

KW - CERN

KW - Medical

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/45015964

U2 - 10.3389/fmed.2021.693682

DO - 10.3389/fmed.2021.693682

M3 - Article

VL - 8

SP - 1

EP - 11

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

M1 - 693682

ER -

ID: 7176204